Steris ( (STE) ) has released its Q3 earnings. Here is a breakdown of the information Steris presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
STERIS plc is a global leader in providing healthcare and life sciences products and services, with a focus on infection prevention, headquartered in Dublin, Ireland.
In its fiscal 2025 third-quarter earnings report, STERIS announced a 6% increase in total revenue from continuing operations, reaching $1.4 billion. The company’s adjusted earnings per share rose to $2.32, signaling strong financial performance.
The Healthcare segment reported a 7% revenue growth, driven by a 9% increase in consumable revenue and a 13% rise in service revenue. However, capital equipment revenue saw a decline of 5%. Applied Sterilization Technologies (AST) posted a 10% increase in revenue, while Life Sciences experienced a decrease of 7% due to divestitures and reduced capital equipment sales. Free cash flow for the first nine months of fiscal 2025 increased to $588.1 million, a significant improvement from the previous year.
Looking ahead, STERIS has adjusted its fiscal 2025 outlook, now expecting a 6% revenue growth, down from the 6.5% to 7.5% previously forecasted, mainly due to currency fluctuations. The company anticipates adjusted earnings per share to be in the range of $9.05 to $9.15, reflecting a cautious yet optimistic financial outlook.
Investors will be keen to follow STERIS’s ability to navigate currency challenges and continue its growth trajectory, with a focus on maintaining strong service and consumable revenue streams.
